Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079482 · ClinicalTrials.gov registry record · Phase 2
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
NCT00079482 is a Phase 2 study that has completed, run by Cephalon. The registered enrollment target is 224 participants.
The verdict
NCT00079482, a Phase 2 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achieve a second complete remission (CR).
Interventions
- DRUG CEP-701
- DRUG high-dose cytarabine
- DRUG Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2003-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079482
The ClinicalTrials.gov registry entry for NCT00079482 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CEP-701 is the first listed.
NCT00079482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079482 about?
NCT00079482 is a clinical study titled "Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)". The purpose of the study is to determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achieve a second complete remission (CR).
What is the current status of trial NCT00079482?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2003-10. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00079482?
The interventions under investigation include: CEP-701 (DRUG), high-dose cytarabine (DRUG), Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy) (DRUG).
Who is sponsoring clinical trial NCT00079482?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.